Alto Neuroscience, Inc. (NYSE:ANRO) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $16.75.

Separately, William Blair reiterated an “outperform” rating on shares of Alto Neuroscience in a research report on Friday, March 21st.

Alto Neuroscience Price Performance

Shares of Alto Neuroscience stock opened at $2.42 on Friday. The firm has a market capitalization of $65.13 million and a PE ratio of -0.95. The company has a current ratio of 13.10, a quick ratio of 13.09 and a debt-to-equity ratio of 0.05. Alto Neuroscience has a 12 month low of $2.37 and a 12 month high of $17.55. The business’s 50-day moving average price is $3.49 and its 200-day moving average price is $5.85.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Thursday, March 20th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.09. Sell-side analysts forecast that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN grew its holdings in Alto Neuroscience by 40.0% in the 4th quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock worth $46,000 after acquiring an additional 3,139 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of Alto Neuroscience by 619.2% in the third quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock worth $49,000 after purchasing an additional 3,715 shares during the last quarter. Deutsche Bank AG increased its holdings in Alto Neuroscience by 31.3% during the 4th quarter. Deutsche Bank AG now owns 15,210 shares of the company’s stock valued at $64,000 after purchasing an additional 3,629 shares during the period. Skandinaviska Enskilda Banken AB publ bought a new position in Alto Neuroscience during the 4th quarter valued at approximately $74,000. Finally, Jane Street Group LLC lifted its holdings in Alto Neuroscience by 72.0% in the 4th quarter. Jane Street Group LLC now owns 18,600 shares of the company’s stock worth $79,000 after buying an additional 7,783 shares during the period.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.